| abstract |
The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: n n n n n n n n n n Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein. |